What changed after the 2022 guidelines for pulmonary hypertension?
Pulmonary hypertension
Risk assessment
Screening
Treatment
Journal
European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
04
08
2023
revised:
18
08
2023
accepted:
22
08
2023
medline:
4
12
2023
pubmed:
7
9
2023
entrez:
6
9
2023
Statut:
ppublish
Résumé
With an estimated prevalence of around 1%, pulmonary hypertension (PH) presents a relevant burden worldwide. In this review, we aim to give an overview of the novelties from the revised European Society of Cardiology (ESC) /European Respiratory Society (ERS) guidelines for the diagnosis and treatment of PH and their implication for the everyday clinical practice.
Identifiants
pubmed: 37673774
pii: S0953-6205(23)00305-9
doi: 10.1016/j.ejim.2023.08.021
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-5Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None of the authors report any conflict of interest in relation to this manuscript. Dr. med. M. Lichtblau reports travel grants and lecture/consultation fees from Johnson and Johnson, Switzerland, MSD and Orpha Swiss outside of the submitted work. Prof. Dr. med. S. Ulrich reports grants from the Swiss National Science Foundation, Zurich Lung, Swiss Lung, Johnson and Johnson, MSD and Orpha Swiss unrelated to the present work. SU received personal fees and travel support from Actelion, MSD, Janssen, Novartis and Orpha Swiss, outside the submitted work.